Apyx Medical Corporation reported a 9% increase in Q3 2026 total revenue, driven by strong Surgical Aesthetics growth, despite a significant decline in its OEM segment. The company also reaffirmed its full-year 2026 revenue guidance, suggesting stability and confidence in its outlook, which could be viewed positively by investors.
Apyx Medical Corporation announced its third-quarter 2026 financial results, showing a 9% year-over-year increase in total revenue to $14.0 million. This growth was primarily fueled by a robust 17% expansion in its Surgical Aesthetics segment, which is a positive indicator for its core business. However, the OEM segment experienced a substantial 42% decline, which could be a point of concern if not addressed. The reaffirmation of the full-year 2026 revenue guidance of $59.0 million to $60.0 million signals management's confidence in achieving its targets, potentially reassuring investors. For traders, the strong performance in Surgical Aesthetics and reaffirmed guidance present a short-term opportunity for positive sentiment, while the OEM segment's weakness could be a long-term risk to monitor.